Overseas Headlines – December 1, 2025

December 1, 2025

 

United States:

UK to Agree Drug Pricing Deal With US, Cut Rebates Paid to NHS

 

The UK is set to announce a pharmaceutical deal with President Donald Trump that includes tariff-free imports to the US, as well as a significant reduction in rebates paid by drugmakers to the National Health Service.

 

The agreement follows prolonged talks between the UK and US governments since Trump complained about the prices Americans pay for imported medicines.

 

https://www.bloomberg.com/news/articles/2025-12-01/uk-to-agree-drug-pricing-deal-with-us-cut-rebates-paid-to-nhs

 

 

Europe:

ECB’s Nagel Says Interest Rates Currently in a ‘Good Place’

 

Governing Council member Joachim Nagel suggested that he’s comfortable with the European Central Bank’s monetary-policy settings.

 

“Our projections also suggest that interest rates are currently in a good place,” the Bundesbank president said Monday in a speech in Seoul, echoing what has become the standard line from ECB officials in recent months. “Eurosystem monetary policy is broadly neutral right now.”

 

https://www.bloomberg.com/news/articles/2025-12-01/ecb-s-nagel-says-interest-rates-currently-in-a-good-place

 

Asia:

BOJ’s Ueda Sends Clear Hint at Chance of December Rate Hike

 

Bank of Japan Governor Kazuo Ueda sent the clearest hint yet that his board might increase interest rates soon, highlighting the possibility of a move at the BOJ’s December meeting.

 

The central bank “will consider the pros and cons of raising the policy interest rate and make decisions as appropriate” by examining the economy, inflation and financial markets at home and abroad, Ueda said Monday in a speech to business leaders in Nagoya, central Japan.

 

https://www.bloomberg.com/news/articles/2025-12-01/boj-s-ueda-sends-clear-hint-at-chance-of-december-rate-hike

 

 

Disclaimer:

Analyst Certification – The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view (s) expressed by that research analyst in this research report.

Company Disclosure – The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein.

2025-12-01T09:10:53-05:00